From: Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy
Dose (Gy) | ||||||||
---|---|---|---|---|---|---|---|---|
All patients | <66 | ≥66 | ||||||
Median | Range | Median | Range | Median | Range | |||
Age at initial diagnosis (years) | 46 | 25–77 | 47 | 26–77 | 44 | 25–77 | ||
Age at LRR (years) | 48 | 25–78 | 50 | 26–78 | 46.5 | 25–77 | ||
F/U from initial diagnosis (mos) | 145 | 6–390 | 140 | 20–382 | 148 | 6–390 | ||
F/U from XRT | 94 | 1–218 | 108 | 1–218 | 92 | 4–164 | ||
Stage | n | % | n | % | n | % | p-value | |
T1 | 55 | 34.6% | 26 | 40.0% | 29 | 30.9% | NS | |
T2 | 76 | 47.8% | 31 | 47.7% | 45 | 47.9% | ||
T3 | 14 | 8.8% | 3 | 4.6% | 11 | 11.7% | ||
T4 | 7 | 4.4% | 2 | 3.1% | 5 | 5.3% | ||
TX | 7 | 4.4% | 3 | 4.6% | 4 | 4.3% | ||
N0 | 81 | 50.9% | 34 | 52.3% | 47 | 50.0% | NS | |
N1 | 52 | 32.7% | 23 | 35.4% | 29 | 30.9% | ||
N2 | 14 | 8.8% | 6 | 9.2% | 8 | 8.5% | ||
N3 | 8 | 5.0% | 1 | 1.5% | 7 | 7.4% | ||
NX | 4 | 2.5% | 1 | 1.5% | 3 | 3.2% | ||
Primary histopathology | ||||||||
IDC | 141 | 88.7% | 56 | 86.2% | 85 | 90.4% | NS | |
ILC | 18 | 11.3% | 9 | 13.8% | 9 | 9.6% | ||
Tumor Grade | ||||||||
Well Diff | 10 | 6.3% | 2 | 3.1% | 8 | 8.5% | NS | |
Mod Diff | 43 | 27.0% | 17 | 26.2% | 26 | 27.7% | ||
Poor Diff | 86 | 54.1% | 37 | 56.9% | 49 | 52.1% | ||
Unk | 20 | 12.6% | 9 | 13.8% | 11 | 11.7% | ||
Markers | ||||||||
ER | ||||||||
Negative | 70 | 44.0% | 34 | 52.3% | 36 | 38.3% | 0.008 | |
Positive | 69 | 43.4% | 19 | 29.2% | 50 | 53.2% | ||
Not done/Unknown | 20 | 12.6% | 12 | 18.5% | 8 | 8.5% | ||
PR | ||||||||
Negative | 69 | 43.4% | 32 | 49.2% | 37 | 39.4% | NS | |
Positive | 65 | 40.9% | 20 | 30.8% | 45 | 47.9% | ||
Not done/Unknown | 25 | 15.7% | 13 | 20.0% | 12 | 12.8% | ||
Her2 | ||||||||
Negative | 30 | 18.9% | 10 | 15.4% | 20 | 21.3% | NS | |
Positive | 15 | 9.4% | 5 | 7.7% | 10 | 10.6% | ||
Unknown/not done | 114 | 71.7% | 50 | 76.9% | 64 | 68.1% | ||
Initial systemic therapy | ||||||||
Hormonal therapy only | 16 | 10.1% | 7 | 10.8% | 9 | 9.6% | 0.05 | |
Chemotherapy only | 66 | 41.5% | 21 | 32.3% | 45 | 47.9% | ||
Chemotherapy and hormonal therapy | 32 | 20.1% | 11 | 16.9% | 21 | 22.3% | ||
None | 45 | 28.3% | 26 | 40.0% | 19 | 20.2% | ||
Initial surgery | ||||||||
MRM | 141 | 88.7% | 59 | 90.8% | 82 | 87.2% | NS | |
Other | 18 | 11.3% | 6 | 9.2% | 12 | 12.8% | ||
Menopausal status | ||||||||
Pre | 67 | 42.1% | 28 | 43.1% | 39 | 41.5% | NS | |
Peri | 18 | 11.3% | 5 | 7.7% | 13 | 13.8% | ||
Post | 63 | 39.6% | 27 | 41.5% | 36 | 38.3% | ||
Unknown | 11 | 6.9% | 5 | 7.7% | 6 | 6.4% | ||
Race | ||||||||
Asian | 11 | 6.9% | 6 | 9.2% | 5 | 5.3% | NS | |
Black | 27 | 17.0% | 7 | 10.8% | 20 | 21.3% | ||
Hispanic | 19 | 11.9% | 11 | 16.9% | 8 | 8.5% | ||
Other | 2 | 1.3% | 1 | 1.5% | 1 | 1.1% | ||
White | 100 | 62.9% | 40 | 61.5% | 60 | 63.8% |